Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07780383
PHASE1

A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration

Sponsor: Bristol-Myers Squibb

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the drug levels, absolute bioavailability, safety, tolerability, and immunogenicity of single-Dose of BMS-986446 in healthy adults after single-dose administration, and participants with early Alzheimer's Disease after multiple dose administration

Official title: A Phase 1, Open-label, Multi-part Study to Evaluate Pharmacokinetics, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 Following Intravenous and Subcutaneous Administrations in Healthy Adults and Multiple Doses of BMS-986446 in Participants With Early Alzheimer's Disease.

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

84

Start Date

2026-08-21

Completion Date

2027-06-17

Last Updated

2026-09-24

Healthy Volunteers

Yes

Interventions

DRUG

BMS-986446

Specified dose on specified days

Locations (6)

CenExel ACT (Formerly Anaheim Clinical Trials; LLC)

Anaheim, California, United States

Local Institution - 0003

Bradenton, Florida, United States

Local Institution - 0005

Daytona Beach, Florida, United States

Local Institution - 0007

Naples, Florida, United States

Local Institution - 0006

The Villages, Florida, United States

Local Institution - 0004

Decatur, Georgia, United States